Three national hospital groups and three hospitals yesterday asked the U.S. Supreme Court to overturn a federal appeals court’s 2-1 July 2020 decision that the nearly 30 percent cut since 2018 in 340B hospitals’ drug reimbursement under the hospital outpatient
…Category: Judicial
The American Hospital Association (AHA) last week told the U.S. Centers for Medicare & Medicaid Services (CMS) that insurance company UnitedHealthcare’s (UHC) specialty pharmacy coverage policies “undermine the intent of the 340B program” and should be disallowed.
In a Feb.
…
The Biden administration late yesterday told the U.S. Supreme Court that, due to the change in the presidency, the federal government has changed its main position in the lawsuit over the Affordable Care Act’s (ACA) constitutionality. The government now says
…
A federal district judge in Oakland, Calif., is scheduled to hold a hearing this afternoon on the U.S. Health and Human Services (HHS) Department’s motion to dismiss a lawsuit against it by 340B hospitals over HHS’s enforcement of its 340B
…The Biden administration and Pharmaceutical Care Management Association (PCMA), the trade association for pharmaceutical benefit managers (PBMs), have agreed to postpone, from January 1, 2022, to January 1, 2023, the effective date of the Trump administration rule eliminating safe harbor
…
The battle in the courts among providers, drug manufacturers, and health officials over 340B contract pharmacy likely will take time to play out, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell (a 340B Report
…
Outgoing U.S. Health and Human Services (HHS) Secretary Alex Azar last week asked a federal district judge to dismiss a lawsuit against him and his department by 340B hospitals over HHS’s enforcement of its 340B contract pharmacy requirements for drug
…
The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications,
…
340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.
…
In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”
As we went to press, we
…